4 Companies That Have Destroyed Shareholders

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
4 Companies That Have Destroyed Shareholders

© Thinkstock

As earnings season is underway, some analysts are expecting earnings disappointments going forward, as S&P Global Market Intelligence expects earnings for the S&P 500 to shrink by about 8% in the first quarter.

So we might be seeing more companies destroying shareholders as this earnings season rolls on. Although the markets have made their comeback, some stocks are still slowing that recovery and punishing their shareholders.

We have picked out some companies that punished shareholders last week. Among the active stocks, these all issued or had news that pushed shares down.

24/7 Wall St. has included their recent trading history, as well as the 52-week trading range and the consensus analyst price target. This week’s list of companies that destroyed shareholders was Sarepta, Netflix, Lakeland and TransEnterix.
[recirclink id=327121]
Sarepta Therapeutics

On Thursday, Sarepta Therapeutics Inc. (NASDAQ: SRPT) watched its shares take a turn for the worse, and then come back and rally on Friday, after the FDA announced that it had some voting questions on Sarepta’s Duchenne muscular dystrophy treatment.

The FDA took a negative view on the drug by adding a voting question, but the stock rallied on Friday following the analysts’ sentiment that there is a light at the end of the tunnel.

Last week, shares of Sarepta were down 29%. The stock closed trading at $14.95 on Friday, with a consensus price target of $24.15 and a 52-week range of $10.20 to $41.97.

Also, here is how one analyst from Janney still sees huge potential upside in Sarepta after its news.

Lakeland Industries

In its fiscal fourth-quarter report posted after the markets closed on Thursday, Lakeland Industries Inc. (NASDAQ: LAKE) reported that it had a net loss of $0.01 per share on $20.5 million in revenue. The consensus estimates called for $0.12 in earnings per share (EPS) on revenue of $24.14 million. In the same period of the previous year, it posted EPS of $0.31 and $24.82 million in revenue.

In the quarter sales dropped compared to last year amid the absence of emergency Ebola-related orders, global economic headwinds and the devaluation of foreign currencies against the U.S. dollar.

The stock fell 19% last week and closed at $9.43 on Friday. The consensus price target is $16.25. The 52-week range is $8.10 to $15.78.

Netflix

After markets closed on Monday, Netflix Inc. (NASDAQ: NFLX) reported first-quarter 2016 results. The video distribution company posted adjusted diluted EPS of $0.06 on revenues of $1.81 billion. In the same period a year ago, the company reported EPS of $0.05 on revenues of $1.57 billion. First-quarter results also compare to the Thomson Reuters consensus estimates for EPS of $0.03 and $1.97 billion in revenues.

In the company’s letter to shareholders, Netflix says U.S. streaming subscriber numbers grew to 45.71 million. Internationally, streaming subscriber numbers grew by 4.55 million to 31.99 million. Total subscribers now number 81.5 million, up by more than 6 million sequentially and just short of 20 million year over year.

The stock dropped 14% over the course of the week. Shares closed Friday at $95.90, with a consensus price target of $118.17 and a 52-week range of $78.89 to $133.27.

TransEnterix

Shares of TransEnterix Inc. (NYSEMKT: TRXC) went into free fall on Thursday morning following a devastating judgment by the U.S. Food and Drug Administration (FDA). The company announced after the markets closed on Wednesday that the FDA notified TransEnterix that it had determined that the SurgiBot System does not meet the criteria for substantial equivalence based on the data and information submitted.

Over the course of the week, the stock was down 64%. Shares of TransEnterix fell to $1.94 to close Friday. The consensus analyst price target is $4.04, and the 52-week trading range is $1.28 to $6.10.

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618